Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Glaucoma is almost 3 times more common in African Americans than in whites.  
  • An estimated 2.2 million Americans age 40 and older have glaucoma– 1.9% of the 40 and older population.  
  • The number of people in the U.S. with visual impairment or blindness is expected to double to more than 8 million by 2050.
     
  • Even mild visual impairment more than doubles the risk of mortality over a 5-year period.  
  • A study of glaucoma patients found that compared with control subjects, they were over 3 times more likely to have fallen in the previous year, over 6 times more likely…